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The additional costs for additional sick leave days were calcu-
lated. Signiﬁcant statistical differences were established in the
cost through a Mann Witney’s U test. RESULTS: A total of 1019
patients were included with an average age of 37  11 years,
49% of which were men. These patients were prescribed with
12,273 sick leave days, the average per patient was 12 days (4–93
days). The total cost of the attention of this patients was of US$
781,806.76. 17.9% of the patients had additional sick leave
days. The average cost of the medical attention of the patients
without additional days was of US$773.74  1135.01 and of the
patients with additional days was of US$737.74  960.38, the
differences were statistically signiﬁcant (p < 0.005). CONCLU-
SIONS: The additional sick leave days have not a signiﬁcant
impact in the attention cost of the patients afﬁliated to the IMSS.
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OBJECTIVES: To examine pharmaceutical expenditure growth
during the years 1980–2006 in Greece in relation to major phar-
maceutical policy changes. METHODS: Data from the OECD
Healthdata database and the National Statistical Service of
Greece were used. Pharmaceutical expenditure data were
deﬂated using the Greek Pharmaceutical Price Index (2005 =
100). Due to the recent revision of the Greek GDP from the
Greek National Statistical Service and Eurostat, data were
divided in two time series, from 1980 to1999 (data not revised)
and from 2000 to 2006 (revised data). Deﬂated data are available
for 1982–1999 and 2000–2006. RESULTS: Pharmaceutical
expenditure mean annual growth rate (MAGR) during the period
1980–1999 was 17.3% and 10.5% from 2000 to 2006. Real
pharmaceutical expenditure MAGR was 9.8% for 1982–1999
and 9.7% for 2000–2006. Pharmaceutical expenditure decreased
by 7.7% from 1997 to 1998 and continued to increase the
following year. Pharmaceutical expenditure growth rates were
higher than the Pharmaceutical Price Index growth rates. Public
pharmaceutical expenditure increased at higher rates compared
to private pharmaceutical expenditure. CONCLUSIONS: Phar-
maceutical expenditure in real values has been constantly rising
during the study period. Pharmaceutical policy reforms intro-
duced in order to contain pharmaceutical expenditure growth
such as the introduction of a positive reimbursement list (1998)
and the pricing of pharmaceuticals at the lowest price of EU
countries (1997) had limited effect. In 2005 a new pricing system
was introduced based on the average of the three lowest EU
prices while in 2006 the positive list was abolished. in relation to
major pharmaceutical policy changes.
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OBJECTIVES: Quality improvement is one mechanism for
reducing health care expenditure. Therefore there is a need for
ranking providers according to their performance. By character-
izing hospital quality by our previously validated composite
measure, to compare the high vs low quality hosptals and their
associated outlier payments. METHODS: Using the national
Medicare claims database for 2006, we examined outlier pay-
ments in patients undergoing coronary artery bypass grafting
(CABG) (n = 104,329). We then categorized hospitals perform-
ing these procedures according to their outlier payment rates.
Using multiple logistic regression, we explored the relationships
between hospital outlier payment rates and hospital quality,
as reﬂected by previously validated composite quality score.
RESULTS: The proportion of patients associated with outlier
payments was 9% (CABG). Average outlier payments were con-
siderable: $19,000 per patient, costing Medicare more than $175
million. Risk adjusted outlier rates for 5-Star Hospitals was only
6.7% whereas low quality hospitals had outlier rates have more
than 11%. CONCLUSIONS: Outlier payments in CABG are an
important component of medical costs with inpatient surgery.
Although persistent differences in billing and accounting prac-
tices maybe an important factor, this differences explained in part
by quality.
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OBJECTIVES: The objective is to obtain a perspective on the
allocation efﬁciency for the local level, and for the system as a
whole. In this direction, data of health ﬁnancing was analyzed
considering its correlation with demand and supply indicators,
and an epidemiological index was designed on the basis of mor-
bidity and mortality. Based on its allocation efﬁciency, a munici-
pality was identiﬁed as a “pattern”, and the performance of each
municipality and the system as a whole was analyzed in front of
it. METHODS: The present study analyzes, on one hand, the
inﬂuence of the indicators of demand and needs in the ﬁnancing
of health in Buenos Aires Province municipalities and, on the
other one, proposes a way to measure the intermunicipal ﬁnanc-
ing gaps. For this, a municipal pattern of efﬁcency is selected
considering the municipality with best results according to health
ﬁnancing. RESULTS: Results show a high correlation between
municipal health expenditures and supply indicators (like hospi-
tal beds), with little incidence of morbidity and mortality, dis-
playing a dissociation between health expenditures and sanitary
needs. In 24 of the 117 municipalities with available information,
health expenditures present as higher than expected considering
their epidemiological proﬁle, whereas the other 93 would be
below their ﬁnancial requirements. In global terms, the system
shows deﬁcit of 1,126 million of Argentinean Pesos (53% supe-
rior to the present budget), with deep gaps among municipalities.
Also, the dispersion in the patterns of health ﬁnancing is high,
reaching a relation of 4.15:1. CONCLUSIONS: The gap between
municipalities requires a cautious analysis in order to identify
successful models of management, that could be replicated to
diminish the system inefﬁciency. Finally, a debate around the
criteria that condition the transference of coparticipables funds
to municipalities is proposed, in order to obtain a greater asso-
ciation between health expenditures and results, with a smaller
transference of risk towards the local levels.
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OBJECTIVES: To identify preventive interventions, not system-
atically implemented, that may be cost-effective in reducing the
Abstracts A373
